Cargando…
Intranasal drug delivery: opportunities and toxicologic challenges during drug development
ABSTRACT: Over the past 10 years, the interest in intranasal drug delivery in pharmaceutical R&D has increased. This review article summarises information on intranasal administration for local and systemic delivery, as well as for CNS indications. Nasal delivery offers many advantages over stan...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829061/ https://www.ncbi.nlm.nih.gov/pubmed/33491126 http://dx.doi.org/10.1007/s13346-020-00891-5 |
_version_ | 1783641110528131072 |
---|---|
author | Keller, Lea-Adriana Merkel, Olivia Popp, Andreas |
author_facet | Keller, Lea-Adriana Merkel, Olivia Popp, Andreas |
author_sort | Keller, Lea-Adriana |
collection | PubMed |
description | ABSTRACT: Over the past 10 years, the interest in intranasal drug delivery in pharmaceutical R&D has increased. This review article summarises information on intranasal administration for local and systemic delivery, as well as for CNS indications. Nasal delivery offers many advantages over standard systemic delivery systems, such as its non-invasive character, a fast onset of action and in many cases reduced side effects due to a more targeted delivery. There are still formulation limitations and toxicological aspects to be optimised. Intranasal drug delivery in the field of drug development is an interesting delivery route for the treatment of neurological disorders. Systemic approaches often fail to efficiently supply the CNS with drugs. This review paper describes the anatomical, histological and physiological basis and summarises currently approved drugs for administration via intranasal delivery. Further, the review focuses on toxicological considerations of intranasally applied compounds and discusses formulation aspects that need to be considered for drug development. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-7829061 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-78290612021-01-25 Intranasal drug delivery: opportunities and toxicologic challenges during drug development Keller, Lea-Adriana Merkel, Olivia Popp, Andreas Drug Deliv Transl Res Original Article ABSTRACT: Over the past 10 years, the interest in intranasal drug delivery in pharmaceutical R&D has increased. This review article summarises information on intranasal administration for local and systemic delivery, as well as for CNS indications. Nasal delivery offers many advantages over standard systemic delivery systems, such as its non-invasive character, a fast onset of action and in many cases reduced side effects due to a more targeted delivery. There are still formulation limitations and toxicological aspects to be optimised. Intranasal drug delivery in the field of drug development is an interesting delivery route for the treatment of neurological disorders. Systemic approaches often fail to efficiently supply the CNS with drugs. This review paper describes the anatomical, histological and physiological basis and summarises currently approved drugs for administration via intranasal delivery. Further, the review focuses on toxicological considerations of intranasally applied compounds and discusses formulation aspects that need to be considered for drug development. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2021-01-25 2022 /pmc/articles/PMC7829061/ /pubmed/33491126 http://dx.doi.org/10.1007/s13346-020-00891-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Keller, Lea-Adriana Merkel, Olivia Popp, Andreas Intranasal drug delivery: opportunities and toxicologic challenges during drug development |
title | Intranasal drug delivery: opportunities and toxicologic challenges during drug development |
title_full | Intranasal drug delivery: opportunities and toxicologic challenges during drug development |
title_fullStr | Intranasal drug delivery: opportunities and toxicologic challenges during drug development |
title_full_unstemmed | Intranasal drug delivery: opportunities and toxicologic challenges during drug development |
title_short | Intranasal drug delivery: opportunities and toxicologic challenges during drug development |
title_sort | intranasal drug delivery: opportunities and toxicologic challenges during drug development |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829061/ https://www.ncbi.nlm.nih.gov/pubmed/33491126 http://dx.doi.org/10.1007/s13346-020-00891-5 |
work_keys_str_mv | AT kellerleaadriana intranasaldrugdeliveryopportunitiesandtoxicologicchallengesduringdrugdevelopment AT merkelolivia intranasaldrugdeliveryopportunitiesandtoxicologicchallengesduringdrugdevelopment AT poppandreas intranasaldrugdeliveryopportunitiesandtoxicologicchallengesduringdrugdevelopment |